The same patient, identified and re-consented for the third or fourth time across separate studies, is not an edge case. It is how clinical research is currently structured, and the inefficiency is measurable: every redundant records request, re-registration, and repeat consent conversation adds cost to the sponsor and time to a patient already managing a demanding diagnosis. The case building around patient-owned health data argues that the architecture itself is the problem, not the execution.
The traditional model treats each protocol as a discrete relationship. A trial opens, participants are found, data flows inward, and the relationship ends. But sponsors rarely stop needing evidence from the same populations once a study closes. Observational work, real-world outcomes, label extensions, and post-market commitments all draw on the same patient groups, rebuilt from scratch each time. What the patient-owned model proposes instead is a single consented relationship that persists across those activities, turning what was an episodic research interaction into ongoing infrastructure. This matters operationally because patients who enter a recruitment funnel late, after considerable sponsor investment in identification and outreach, still fail screening at meaningful rates for avoidable reasons. Earlier access to consented, longitudinal data lets sponsors assess eligibility signals before a protocol opens, not after.
Interoperability is what makes any of this plausible at scale. ONC data shows that 69% of US hospitals had adopted FHIR-based applications enabling patient data access by 2024, up from 56% in 2021. That adoption rate means a growing share of patients can already pull their records across provider, pharmacy, and payer systems into a single view. When patients control that aggregated record and choose to share it for research purposes, sponsors gain visibility into treatment history, diagnostic timelines, and care transitions that a site chart review would miss entirely. The research signal improves; the administrative drag on sites shrinks.
The model described here, sometimes called a “virtual patient waiting room,” is essentially a standing cohort built from continuous engagement rather than episodic recruitment. Each survey response or patient-reported outcome collected between studies strengthens the data asset for the next one. FDA guidance on PRO data submission in oncology trials signals that regulators already accept patient-direct reporting as evidence. The practical test for this model is whether the patient relationship actually persists once a given study closes, or whether sponsors revert to rebuilding it when the next protocol opens.
Source link: https://mytomorrows.com/blog/biopharma/patient-owned-health-data-is-reshaping-clinical-research/
Patient-Owned Health Data: the facts in one place
- Also written: POHD, Patient-Generated Health Data, PGHD, patient-mediated data exchange, patient experience data, PED, real-world data, RWD
- Registry identifier: not publicly listed
- Current status: Conceptual framework under active regulatory development; EMA and FDA are developing guidance on patient experience data and real-world data integration into regulatory decision-making, with EMA public consultation open until January 31, 2026.
- HIPAA enacted: 1996
- FDA guidance on manufacturers sharing patient-specific device data issued: October 2017
- FDA guidance on manufacturers sharing patient-specific device data content current as of: January 10, 2018
- NIH Genomic Data Sharing Policy enacted: 2014
Moe Alsumidaie, MBA, MSF, is founder and Chief Editor of Vanguard Publications, which publishes Clinical Trial Vanguard, Pharma Vanguard and BullScope, and Head of Research at CliniBiz. He has two decades in clinical trial operations and data science, with earlier roles at Genentech, Abbott Vascular and Stanford University Medical Center, and is a guest lecturer in clinical trial sciences at Rutgers University.
